Suppr超能文献

采用改良的基于细胞培养的方法测定古巴近期生殖支原体分离株的抗菌药敏模式。

Antimicrobial Susceptibility Patterns of Recent Cuban Mycoplasma genitalium Isolates Determined by a Modified Cell-Culture-Based Method.

作者信息

Mondeja Brian A, Rodríguez Nadia M, Barroto Brenda, Blanco Orestes, Jensen Jørgen S

机构信息

Pedro Kourí Tropical Medicine Institute, La Habana, Cuba.

Biology Faculty, University of Havana, La Habana, Cuba.

出版信息

PLoS One. 2016 Sep 28;11(9):e0162924. doi: 10.1371/journal.pone.0162924. eCollection 2016.

Abstract

Isolation of Mycoplasma genitalium from clinical specimens remains difficult and few strains are available for antimicrobial susceptibility testing. We describe the antimicrobial susceptibility of M. genitalium strains grown in Vero cell culture with first- and second- line antibiotics, using a modified cell-culture-based method. Macrolide- and -fluoroquinolone resistance determinants were detected by sequencing of the 23S and parC genes, respectively. Seven strains were examined, including three new, genetically distinct M. genitalium strains isolated from endocervical and urethral swab specimens from Cuban patients together with four reference strains isolated from specimens collected from men in Denmark, Sweden and Australia. Azithromycin was the most active drug against two of the Cuban M. genitalium strains with MICs values of 0.008 mg/liter, however, one strain was macrolide resistant with an MIC of >8 mg/liter, and the A2059G resistant genotype. Ciprofloxacin was the least active antimicrobial drug and moxifloxacin was the most active fluoroquinolone against the new clinical strains, although an MIC of 1 mg/l was found for two strains. However, no relevant parC mutations were detected. MICs for tetracyclines were 0.5-4 mg/liter. Although the number of Cuban strains was low, the results suggest that a single-dose azithromycin treatment could be ineffective, and that a second-line treatment with moxifloxacin, should become an option in Cuba. To our knowledge, this is the first report of isolation and antibiotic susceptibility testing of M. genitalium strains from the Latin-American region, and the first detection of macrolide resistance in such strains.

摘要

从临床标本中分离生殖支原体仍然困难,可供进行抗菌药敏试验的菌株很少。我们使用改良的基于细胞培养的方法,描述了在Vero细胞培养物中生长的生殖支原体菌株对一线和二线抗生素的药敏情况。分别通过对23S和parC基因进行测序来检测大环内酯类和氟喹诺酮类耐药决定簇。共检测了7株菌株,包括从古巴患者的宫颈和尿道拭子标本中分离出的3株新的、基因不同的生殖支原体菌株,以及从丹麦、瑞典和澳大利亚男性标本中分离出的4株参考菌株。阿奇霉素对其中两株古巴生殖支原体菌株活性最强,MIC值为0.008毫克/升,然而,有一株菌株对大环内酯耐药,MIC>8毫克/升,且具有A2059G耐药基因型。环丙沙星是活性最低的抗菌药物,莫西沙星是对新临床菌株活性最强的氟喹诺酮类药物,不过有两株菌株的MIC为1毫克/升。然而,未检测到相关的parC突变。四环素类的MIC为0.5 - 4毫克/升。尽管古巴菌株数量较少,但结果表明单剂量阿奇霉素治疗可能无效,在古巴莫西沙星二线治疗应成为一种选择。据我们所知,这是拉丁美洲地区生殖支原体菌株分离及抗生素药敏试验的首次报告,也是此类菌株中首次检测到大环内酯耐药。

相似文献

1
2
Antibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5' nuclease real-time PCR.
Antimicrob Agents Chemother. 2005 Dec;49(12):4993-8. doi: 10.1128/AAC.49.12.4993-4998.2005.
3
Mutations in ParC and GyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strains.
PLoS One. 2018 Jun 8;13(6):e0198355. doi: 10.1371/journal.pone.0198355. eCollection 2018.
4
Macrolide-resistant Mycoplasma genitalium infections in Cuban patients: an underestimated health problem.
BMC Infect Dis. 2018 Nov 29;18(1):601. doi: 10.1186/s12879-018-3523-9.
5
Macrolide and fluoroquinolone resistance in Mycoplasma genitalium in two Swedish counties, 2011-2015.
APMIS. 2018 Feb;126(2):123-127. doi: 10.1111/apm.12792. Epub 2017 Dec 13.
6
Remarkable increase in fluoroquinolone-resistant Mycoplasma genitalium in Japan.
J Antimicrob Chemother. 2014 Sep;69(9):2376-82. doi: 10.1093/jac/dku164. Epub 2014 Jun 2.
8
Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance.
Int J STD AIDS. 2013 Oct;24(10):822-8. doi: 10.1177/0956462413502008. Epub 2013 Aug 29.

引用本文的文献

1
Factors that contribute to the success of primary isolation of from clinical samples.
J Med Microbiol. 2025 Jul;74(7). doi: 10.1099/jmm.0.002040.
4
: A new superbug.
Indian J Sex Transm Dis AIDS. 2022 Jan-Jun;43(1):1-12. doi: 10.4103/ijstd.ijstd_103_20. Epub 2022 Jun 7.
6
Macrolide-resistant Mycoplasma genitalium infections in Cuban patients: an underestimated health problem.
BMC Infect Dis. 2018 Nov 29;18(1):601. doi: 10.1186/s12879-018-3523-9.
7
infections: current treatment options and resistance issues.
Infect Drug Resist. 2017 Sep 1;10:283-292. doi: 10.2147/IDR.S105469. eCollection 2017.

本文引用的文献

1
Management of Mycoplasma genitalium infections - can we hit a moving target?
BMC Infect Dis. 2015 Aug 19;15:343. doi: 10.1186/s12879-015-1041-6.
2
High levels of macrolide resistance-associated mutations in Mycoplasma genitalium warrant antibiotic susceptibility-guided treatment.
J Antimicrob Chemother. 2015 Sep;70(9):2515-8. doi: 10.1093/jac/dkv136. Epub 2015 May 20.
3
Isolation of Mycoplasma genitalium from patients with urogenital infections: first report from the Latin-American region.
New Microbes New Infect. 2013 Nov;1(2):22-6. doi: 10.1002/2052-2975.20. Epub 2013 Nov 28.
4
Mycoplasma genitalium testing pattern and macrolide resistance: a Danish nationwide retrospective survey.
Clin Infect Dis. 2014 Jul 1;59(1):24-30. doi: 10.1093/cid/ciu217. Epub 2014 Apr 11.
5
In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.
Antimicrob Agents Chemother. 2014 Jun;58(6):3151-6. doi: 10.1128/AAC.02411-14. Epub 2014 Mar 17.
6
Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium.
J Clin Microbiol. 2013 Jul;51(7):2245-9. doi: 10.1128/JCM.00495-13. Epub 2013 May 8.
7
Treatment of Mycoplasma genitalium. Observations from a Swedish STD clinic.
PLoS One. 2013 Apr 8;8(4):e61481. doi: 10.1371/journal.pone.0061481. Print 2013.
8
Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium.
Antimicrob Agents Chemother. 2013 Apr;57(4):1772-6. doi: 10.1128/AAC.01956-12. Epub 2013 Jan 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验